Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study

Vokó, Zoltán; Kiss, Zoltán; Surján, György; Surján, Orsolya; Barcza, Zsófia; Pályi, Bernadett; Formanek-Balku, Eszter; Molnár, Gergő Attila; Herczeg, Róbert; Gyenesei, Attila; Miseta, Attila; Kollár, László P.; Wittmann, István; Müller, Cecília; Kásler, Miklós

doi:10.1016/j.cmi.2021.11.011

Cited by 103 publications

(142 citation statements)

References 22 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Of particular importance is the well-designed, large-sample observational cohort study from Vokó et al [ 55 ] which investigated, among others, the Sinopharm vaccine’s real-life clinical effectiveness in Hungary between 22 January 2021 and 10 June 2021, and presented the results stratified according to fine-resolution age groups. This study is particularly interesting as it discusses the same vaccine in the same population and in the same time period, but uses a clinical outcome, thus it provides a unique opportunity to contrast antibody levels with clinical protection.…”

Section: Discussionmentioning

confidence: 99%

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Ferenci

Sarkadi

2022

BMC Infect Dis

View full text Add to dashboard Cite

Background Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. Methods RBD-specific antibody titres, as a rapidly available and highly predictive surrogate marker, were measured after two doses of the BBIBP-CorV vaccine in 450 subjects. Results were analyzed in a multivariable model accounting for age, sex and time since the administration of the second dose of the vaccine. Results Sex and time since the second dose had little association with the antibody titres. Age, however, was highly relevant: measurable antibody levels were present in about 90% of individuals below the age of 50, but antibody production after BBIBP-CorV vaccination was strongly reduced with increasing age. A large number of elderly subjects, reaching 25% at 60 years, and up to 50% at ages over 80, were found not to produce any protective antibody. Conclusions RBD-specific antibody titre, as a correlate of protection for COVID-19 disease susceptibility, should help to evaluate the effectiveness of the BBIBP-CorV vaccine. Results suggest that proper measures should be undertaken to prevent a potential outbreak of COVID-19 in BBIBP-CorV vaccinated but eventually unprotected elderly individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Ferenci

Sarkadi

2022

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…No reactogenicity study was conducted in this study (17). A retrospective observational study conducted in Hungary investigated the efficacy of Sputnik V (Gam-COVID-Vac), Sinopharm the Sinopharm (BBIBP-CorV) vaccine was 68.7% effective against SARS-CoV-2 infection and 67.3-100% effective against COVID-19 deaths (depending on age cohort) [18].…”

Section: (Which Was Not Certified By Peer Review)mentioning

confidence: 99%

Comparative study of immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in Belarus

Stoma

Korsak

Воропаев

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: Lack of comparative studies on efficiency of a broad range of COVID19 vaccines leads to lower levels of adoption and subsequent lower total immunity in several regions, including Republic of Belarus. This clinical study captures and transparently demonstrates varying immunogenic responses to Sputnik V and Sinopharm vaccines. Aim of this study was: to compare the immunogenicity and reactogenicity of Sputnik V (Gam-COVID-Vac), RF and Sinopharm (BBIBP-CorV), PRC vaccines in vaccinated individuals. Materials and Methods: A total of 60 adults participated the study. The immune response after vaccination was assessed using enzyme immunoassay. IgG levels measured in all participants at three time points: before the vaccination, 42 days after the first vaccine dose, and 6 months after the first vaccine dose. The results of the SARS-CoV-2 antibody test is quantified according to the WHO First International Standard (NIBSC code:20/136) and expressed in international units (BAU/ml). Results: The study participants were divided into two groups, where 30 people (50%) were vaccinated with Sputnik V (Gam-COVID-Vac), and 30 people were vaccinated with Sinopharm (BBIBP-CorV), with no gender differences in the groups. The IgG levels at 42 days after the first vaccine dose were: Sputnik V (Gam-COVID-Vac)(42 days): Me=650.4 (642.2-669.4); Sinopharm (BBIBP-CorV)(42 days): Me=376.5 (290.9-526.4); p<0,001). The IgG levels at 6 months after the first vaccine dose were: Sputnik V (Gam-COVID-Vac)(6 months) Me=608.7 (574.6-647.1); Sinopharm (BBIBP-CorV)(6 months): Me=106.3 (78.21-332.4); p<0,001). Reactions after vaccination appeared in 27 vaccinated individuals (45%). Conclusion: The study showed that Sputnik V (Gam-COVID-Vac) vaccine was more immunogenic than Sinopharm (BBIBP-CorV) vaccine. IgG levels in vaccinated individuals who previously recovered from SARS-CoV-2 infection ("hybrid immunity") were higher than in SARS-CoV-2 naive individuals. Reactions after vaccines administration were mild to moderate.

show abstract

“…However, we will highlight some factors that have contributed to this variation. The most important factor is the emergence of vaccination (Vokó et al, 2021). The vaccination program, which started in January of 2021, allowed older people and those in priority professions to enroll first, and gradually opened enrolment to younger age groups.…”

Section: Figure 4: Age-specific Excess Mortality Ratementioning

confidence: 99%

“…The literature describes three distinct waves of different viral variants during the period studied: the first was relatively mild in Hungary during the spring of 2020; the second wave, which started in autumn 2020; and the third wave, which started in February 2021.The latter two waves coincided with the winter 2020-2021 influenza epidemic, which was milder than usual due to the protective measures that had been instated against COVID-19 (Frisckle et al, 2021;Kung et al, 2021). In addition, mortality trends (in a positive direction) were significantly influenced by the vaccination program that started in early 2021 (Vokó et al, 2021), which resulted in nearly 60% of the population becoming vaccinated by the end of September 2021.…”

Section: Introductionmentioning

confidence: 99%

“…Many recent publications have described the impact of the pandemic on mortality in Hungary from different perspectives. Some have investigated the spread of the pandemic (Röst et al, 2020;Pintér et al, 2020) and the effectiveness of vaccines (Vokó et al, 2021); others have approached the issue from the perspective of comorbidities and other causes of death (Ostváth et al, 2021;Horváth et al, 2022), the insurance sector (Csépai and Kovács, 2021), and historical experience (Váradi et al, 2020). The geographical spread of the pandemic has also been given particular attention.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Narrowing gap in regional and age-specific excess mortality in the first year and a half of COVID-19 in Hungary

Tóth

2022

Preprint

View full text Add to dashboard Cite

In the first year and a half of the pandemic, the excess mortality in Hungary was 28,400, which was 1,700 lower than the official statistics on COVID-19 deaths. This discrepancy can be partly explained by protective measures instated during the COVID-19 pandemic that decreased the intensity of the seasonal flu outbreak, which caused on average 3,000 deaths per year. Compared to the second wave of the COVID-19 pandemic, the third wave showed a reduction in the differences in excess mortality between age groups and regions. The excess mortality rate for people aged 75+ fell significantly in the third wave, partly due to the vaccination schedule and the absence of a normal flu season. For people aged 40-77, the excess mortality rate rose slightly in the third wave. Between regions, excess mortality was highest in Northern Hungary and Western Transdanubia, and much lower in Central Hungary, where the capital is located. The excess mortality rate for men was almost twice as high as that for women in almost all age groups.

show abstract

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study

Cited by 103 publications

References 22 publications

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Comparative study of immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in Belarus

Narrowing gap in regional and age-specific excess mortality in the first year and a half of COVID-19 in Hungary

Contact Info

Product

Resources

About